Skip to main content
Premium Trial:

Request an Annual Quote

Number in Error

The US Food and Drug Administration misstated how many coronavirus patients a study showed would be helped by treatment with convalescent plasma, the New York Times reports.

The agency issued an Emergency Use Authorization for the treatment on Sunday, a decision President Donald Trump hailed as "truly historic," according to CNN. It adds that during the briefing, US Health and Human Services Secretary Alex Azar said study data from 70,000 volunteers indicated treatment with convalescent plasma led to a 35 percent increase in survival.

But that number — which the Washington Post notes was repeated by FDA Commissioner Stephen Hahn — has been called into question, it adds. The number, it says, appears to come from a confusion of absolute versus relative risk, and only refers to a subset of patients in the Mayo Clinic study.

Hahn acknowledged the error in a tweet, the Post adds."I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma. The criticism is entirely justified," Hahn writes on Twitter. "What I should have said better is that the data show a relative risk reduction not an absolute risk reduction.

CNN adds that the study instead found 8.7 percent of patients who were treated with convalescent plasma within three days being diagnosed died, while 12 percent of patients who were treated four days or more after being diagnosed died. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.